Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
GlaxoSmithKline
Philippe Gevaert; Martin Desrosiers; Marjolein Cornet; Joaquim Mullol; Eugenio De Corso; Nesil Keles Turel; Jorge Maspero; Shigeharu Fujieda; Luo Zhang; Ana R Sousa; Samantha J Woods; Angela M Davis; Stein Schalkwijk; Dawn Edwards; Prerna Ranganathan; Richard Follows; Carolynne Marshall; Joseph K Han; ANCHOR-1 and ANCHOR-2 trial investigators
Biostatistics, Respiratory & Immunology Unit, GSK, London, UK. ; Biostatistics, Respiratory & Immunology Unit, GSK, Upper Providence, PA, USA.